No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

被引：0
|
作者：
Deodhar, Atul A. [1 ]
Schreiber, Stefan [2 ]
Gandhi, Kunal [3 ]
Fox, Todd [4 ]
Gaillez, Corine [4 ]
Karyekar, Chetan [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Christian Albrechts Univ Kiel, Kiel, Germany
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
962
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
    Gottlieb, Alice B.
    Deodhar, Atul
    Mcinnes, Iain B.
    Baraliakos, Xenofon
    Reich, Kristian
    Schreiber, Stefan
    Bao, Weibin
    Marfo, Kwaku
    Richards, Hanno B.
    Pricop, Luminita
    Shete, Abhijit
    Trivedi, Vivek
    Keefe, Deborah
    Papavassilis, Charis C.
    Jagiello, Piotr
    Papanastasiou, Philemon
    Mease, Philip J.
    Lebwohl, Mark
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [32] Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: Data from 3 large randomized clinical trials
    Gooderham, Melinda
    Elewski, Boni
    Pariser, David
    Sofen, Howard
    Mendelsohn, Alan
    Cichanowitz, Nicole
    Li, Qing
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB166 - AB166
  • [33] IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM FUTURE 2 AND FUTURE 3 PHASE 3 STUDIES
    McInnes, Iain B.
    Wallman, Johan K.
    Schett, Georg
    Quebe-Fehling, Erhard
    Rasouliyan, Lawrence
    Pricop, Luminita
    Fasth, Andreas E.
    Gaillez, Corine
    RHEUMATOLOGY, 2019, 58
  • [34] SECUKINUMAB REDUCES HSCRP LEVELS IN SUBJECTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND CONCOMITANT PSORIATIC ARTHRITIS: A SUB-ANALYSIS FROM THE PHASE 3 ERASURE STUDY
    Gottlieb, A.
    Sigurgeirsson, B.
    Blauvelt, A.
    Gong, Y.
    Papavassilis, C.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1047 - 1048
  • [35] Effect of secukinumab on psoriasis symptoms and physical functioning compared with placebo and etanercept in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis from the phase 3 fixture study
    Sigurgeirsson, B.
    Gottlieb, A. B.
    Langley, R. G.
    Philipp, S.
    Martin, R. L. M.
    Papavassilis, C.
    Mpofu, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 64 - 65
  • [36] Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture Study
    Gottlieb, Alice
    Langley, Richard
    Philipp, Sandra
    Martin, Ruvie
    Papavassilis, Charis
    Mpfofu, Shephard
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3322 - 3322
  • [37] Safety of Bimekizumab in Patients with moderate to severe Psoriasis: Analysis of Pooled Data from Phase II and III Clinical Studies
    Reich, K.
    Blauvelt, A.
    Lebwohl, M.
    Papp, K. A.
    Rich, P.
    Strober, B.
    De Cuyper, D.
    Madden, C.
    Peterson, L.
    Vanvoorden, V.
    Warren, R. B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 64 - 64
  • [38] Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System
    Penso, Laetitia
    Bergqvist, Christina
    Meyer, Antoine
    Herlemont, Philippe
    Weill, Alain
    Zureik, Mahmoud
    Dray-Spira, Rosemary
    Sbidian, Emilie
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (02) : 244 - 252
  • [39] IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM TWO PHASE 3 STUDIES (FUTURE 2 AND FUTURE 3)
    Wallman, J. K.
    Schett, G.
    McInnes, I. B.
    Quebe-Fehling, E.
    Rasouliyan, L.
    Pricop, L.
    Fasth, A. E.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 373 - 374
  • [40] Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3)
    Wallman, J. K.
    Schett, G.
    McInnes, I. B.
    Quebe-Fehling, E.
    Rasouliyan, L.
    Pricop, L.
    Gaillez, C.
    Fasth, A. E.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 36 - 37
12345